Lilly’s LOXO-292, an experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene. The results, presented this week at the World Lung Conference in Barcelona, will support Lilly’s application for U.S. FDA approval later this year. Lilly plans to present data on patients with two kinds of thyroid cancers that carry RET alterations at the European Society for Medical Oncology meeting in Barcelona later this month. The company will file for FDA-approval of the drug in all three indications by the end of this year. Learn More